Gilead voluntarily withdraws urothelial cancer drug in US

(Reuters) – Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients with a type of urothelial cancer after consultation with the regulator.

(Reporting by Sneha S K)